Financials in USD. Standardized financial statements.
A compact view of how Impact BioMedical Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue? | $32,000 | $1.62M | $0 | $0 | $0 | $0 |
| Revenue Growth? | -98.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $424,000 | $0 | $0 | $1.11M | $1.11M | $0 |
| Gross Profit? | -$392,000 | $1.62M | $0 | -$1.11M | -$1.11M | $0 |
| Gross Margin? | -1225.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $3.88M | $1.24M | $4.03M | $2.34M | $2.07M | $896,727 |
| Operating Income? | -$4.27M | $383,351 | -$4.03M | -$3.45M | -$3.19M | -$896,727 |
| EBITDA? | -$12.51M | -$1.07M | -$2.84M | -$2.34M | -$2.07M | -$896,727 |
| Income Before Tax | -$14.45M | -$1.43M | -$4.41M | -$7.88M | -$3.24M | -$896,727 |
| Income Tax Expense | -$2.58M | $33,000 | $0 | -$621,000 | -$1.40M | -$82,000 |
| Net Income? | -$11.84M | -$1.43M | -$4.34M | -$7.05M | -$1.30M | -$597,342 |
| EPS? | $-0.38 | $-0.01 | $-0.07 | $-0.61 | $-0.61 | $-0.05 |
| Diluted EPS? | $-0.38 | $-0.01 | $-0.07 | $-0.61 | $-0.61 | $-0.05 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality